drugset / Trial / NCT00507936

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00507936

Phase 2 Completed 280 enrolled AbbVie
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study at approximately 50 sites in both the United States and Europe. The study will be divided into the following periods: Screening/Washout (21 days) followed by a Baseline Visit, an 8-week Treatment Period and a 1-week Follow-up Visit.

Timeline

Start
2007-08
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg
Subject SOFINICLINE Small molecule 1 mg
Subject SOFINICLINE Small molecule 2 mg
Subject SOFINICLINE Small molecule 4 mg